Usha Chandrahasa, MD
Allergy & Immunology · Port Charlotte, FLNPI 1548254857
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,679 of the $105,503 with a category attached, or 73.6%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 60.5% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $31,051 and has fallen 98.1% since, to $602 in 2025. Among allergy & immunology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $352.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$64K
- Shire North American Group Inc$18K
- Genentech USA, Inc.$15K
- Boehringer Ingelheim$3K
- Sanofi$2K
- AstraZeneca$895
- plus $3K from 23 others
What the payments were for
- Consulting fees$3,6213%
- Speaking & faculty fees$77,67974%
- Travel & lodging$15,93915%
- Food & beverage$8,0438%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 67 | $63,855 |
| Shire North American Group Inc | 31 | $17,780 |
| Genentech USA, Inc. | 35 | $15,274 |
| Boehringer Ingelheim | 12 | $3,281 |
| Sanofi | 19 | $1,592 |
| AstraZeneca | 30 | $895 |
| GSK | 28 | $618 |
| CSL Behring | 20 | $556 |
| Regeneron Healthcare Solutions, Inc. | 10 | $312 |
| Pharming Healthcare, Inc. | 6 | $194 |
| ADMA Biomanufacturing LLC | 2 | $194 |
| Grifols USA, LLC | 4 | $146 |
| Pfizer | 7 | $119 |
| Sanofi-aventis U.S. LLC | 1 | $111 |
| Novartis | 4 | $87 |
| Boston Scientific | 1 | $82 |
| Amgen | 3 | $61 |
| Mylan Specialty L.p. | 3 | $53 |
| Optinose US, Inc. | 3 | $51 |
| Kaleo, Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 1 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Octapharma USA, Inc. | 1 | $27 |
| Ionis Pharmaceuticals, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $21 |
| Insmed, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Biocryst US Sales Co., LLC | 1 | $14 |
| Mylan Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,503 in reported general payments places this provider in the 90th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 153 | $155,008 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $117,318 |
| Advair HfaFluticasone Propion/Salmeterol | 244 | $112,062 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $104,274 |
| Dupixent SyringeDupilumab | 23 | $85,859 |
| Spiriva RespimatTiotropium Bromide | 76 | $69,163 |
| Breo ElliptaFluticasone/Vilanterol | 115 | $63,711 |
| SymbicortBudesonide/Formoterol Fumarate | 119 | $45,527 |
| DuleraMometasone/Formoterol | 63 | $35,473 |
| Arnuity ElliptaFluticasone Furoate | 104 | $32,307 |
| Azelastine Hcl | 940 | $23,115 |
| BreynaBudesonide/Formoterol Fumarate | 92 | $22,720 |
| Qvar RedihalerBeclomethasone Dipropionate | 46 | $16,704 |
| Fluticasone Propionate | 1,067 | $14,051 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $11,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta, Anoro Ellipta | $618 | $217,886370 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $895 | $200,534272 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $63,855 | $117,31813 claims |
| Boehringer IngelheimSpiriva Respimat | $3,281 | $69,16376 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $42 | $16,70446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Port Charlotte
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.